Literature DB >> 7507889

Mapping of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG.

K Huygen1, E Lozes, B Gilles, A Drowart, K Palfliet, F Jurion, I Roland, M Art, M Dufaux, J Nyabenda.   

Abstract

TH1 cytokine secretion was examined in response to synthetic peptides of the 85A component of the major secreted, fibronectin-binding antigen 85 complex from Mycobacterium tuberculosis in seven different mouse strains infected with live M. bovis BCG. Twenty-eight overlapping 20-mer peptides covering the complete mature 295-amino-acid (AA) protein were synthesized. Significant interleukin-2 (IL-2) and gamma interferon (IFN-gamma) secretion could be measured following in vitro stimulation of spleen cells with these peptides. H-2d haplotype mice reacted preferentially against the amino-terminal half of the protein, i.e., against peptide 5 (AA 41 to 60) and especially against peptide 11 (AA 101 to 120), which contained an I-Ed binding motif. H-2b haplotype mice, on the other hand, reacted against peptides from both amino- and carboxy-terminal halves of the protein, peptide 25 (AA 241 to 260) being the most potent stimulator of IL-2 and IFN-gamma production. (BALB/c x C57BL/6)F1 animals with the H-2d/b haplotype weakly recognized peptides specific for both parental lines. Finally, CBA/J (H-2k) and major histocompatibility complex class II mutant B6.C.bm12 mice, carrying a mutant I-A beta bm12 allele on an H-2b background, reacted only very weakly to the 85A peptides. Reactive T cells isolated from lungs of BCG-infected H-2b haplotype mice recognized the same epitopes as spleen cells, especially peptide 25. These data confirm previous findings regarding the powerful IL-2 and IFN-gamma-inducing properties of antigen 85 during infection with live M. bovis BCG.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507889      PMCID: PMC186116          DOI: 10.1128/iai.62.2.363-370.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Viability and multiplication of vaccines in immunization against tuberculosis.

Authors:  H BLOCH; W SEGAL
Journal:  Am Rev Tuberc       Date:  1955-02

2.  A multidot immunobinding assay for the serodiagnosis of tuberculosis. Comparison with an enzyme-linked immunosorbent assay.

Authors:  J P Van Vooren; M Turneer; J C Yernault; J De Bruyn; E Burton; F Legros; C M Farber
Journal:  J Immunol Methods       Date:  1988-10-04       Impact factor: 2.303

Review 3.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.

Authors:  G B Fields; R L Noble
Journal:  Int J Pept Protein Res       Date:  1990-03

4.  The major secreted antigen complex (Ag 85) from Mycobacterium bovis bacille Calmette-Guérin is associated with protective T cells in leprosy: a follow-up study of 45 household contacts.

Authors:  P Launois; M N Niang; J De Bruyn; J L Sarthou; F Rivier; A Drowart; J P Van Vooren; J Millan; K Huygen
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

5.  T cell response to purified filtrate antigen 85 from Mycobacterium bovis Bacilli Calmette-Guérin (BCG) in leprosy patients.

Authors:  P Launois; K Huygen; J De Bruyn; M N'Diaye; B Diouf; L Sarthouj; J Grimaud; J Millan
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

6.  Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by Mycobacterium leprae.

Authors:  J E Thole; R Schöningh; A A Janson; T Garbe; Y E Cornelisse; J E Clark-Curtiss; A H Kolk; T H Ottenhoff; R R De Vries; C Abou-Zeid
Journal:  Mol Microbiol       Date:  1992-01       Impact factor: 3.501

7.  Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines.

Authors:  I M Orme
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

Review 8.  The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis.

Authors:  H G Wiker; M Harboe
Journal:  Microbiol Rev       Date:  1992-12

9.  Biological activity of protein antigens isolated from Mycobacterium tuberculosis culture filtrate.

Authors:  F M Collins; J R Lamb; D B Young
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

10.  Specific lymphoproliferation, gamma interferon production, and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis.

Authors:  K Huygen; J P Van Vooren; M Turneer; R Bosmans; P Dierckx; J De Bruyn
Journal:  Scand J Immunol       Date:  1988-02       Impact factor: 3.487

View more
  42 in total

1.  BCG infection in allergen-presensitized rats suppresses Th2 immune response and prevents the development of allergic asthmatic reaction.

Authors:  Y I Koh; I S Choi; W Y Kim
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

2.  Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens recognized early upon infection in mice and cattle.

Authors:  Valérie Rosseels; Sylvie Marché; Virginie Roupie; Marc Govaerts; Jacques Godfroid; Karl Walravens; Kris Huygen
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Genetic toggling of alkaline phosphatase folding reveals signal peptides for all major modes of transport across the inner membrane of bacteria.

Authors:  Matthew Marrichi; Luis Camacho; David G Russell; Matthew P DeLisa
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

4.  Cyclipostins and cyclophostin analogs inhibit the antigen 85C from Mycobacterium tuberculosis both in vitro and in vivo.

Authors:  Albertus Viljoen; Matthias Richard; Phuong Chi Nguyen; Patrick Fourquet; Luc Camoin; Rishi R Paudal; Giri R Gnawali; Christopher D Spilling; Jean-François Cavalier; Stéphane Canaan; Mickael Blaise; Laurent Kremer
Journal:  J Biol Chem       Date:  2018-01-04       Impact factor: 5.157

5.  Identification of amino acid residues of the T-cell epitope of Mycobacterium tuberculosis alpha antigen critical for Vbeta11(+) Th1 cells.

Authors:  A Kariyone; K Higuchi; S Yamamoto; A Nagasaka-Kametaka; M Harada; A Takahashi; N Harada; K Ogasawara; K Takatsu
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

6.  Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines.

Authors:  A S Mustafa; F A Shaban; A T Abal; R Al-Attiyah; H G Wiker; K E Lundin; F Oftung; K Huygen
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

7.  Epitope focus, clonal composition and Th1 phenotype of the human CD4 response to the secretory mycobacterial antigen Ag85.

Authors:  M T Valle; A M Megiovanni; A Merlo; G Li Pira; L Bottone; G Angelini; L Bracci; L Lozzi; K Huygen; F Manca
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

8.  Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis.

Authors:  Andrea Cruz; Alexandra G Fraga; Jeffrey J Fountain; Javier Rangel-Moreno; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Troy D Randall; Jorge Pedrosa; Andrea M Cooper; António G Castro
Journal:  J Exp Med       Date:  2010-07-12       Impact factor: 14.307

9.  Heterologous expression of the Mycobacterium tuberculosis gene encoding antigen 85A in Corynebacterium glutamicum.

Authors:  K Salim; V Haedens; J Content; G Leblon; K Huygen
Journal:  Appl Environ Microbiol       Date:  1997-11       Impact factor: 4.792

10.  Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection.

Authors:  Edward O Ronan; Lian Ni Lee; Peter C L Beverley; Elma Z Tchilian
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.